The DOI matches its Crossref record.
Antitumour Metallocenes: Structure-Activity Studies and Interactions with Biomolecules.
Abstract
The metallocene dihalides are a relatively new class of small, hydrophobic organometallic anticancer agents that exhibit antitumour properties against numerous cell lines including leukemias P388 and L1210, colon 38 and Lewis lung carcinomas, B16 melanoma, solid and fluid Ehrlich ascites tumours and several human colon and lung carcinomas transplanted into athymic mice. Titanocene dichloride 1 has been the most widely studied metallocene and the drug is currently in phase II clinical trials. Formation of metallocene-DNA complexes has been implicated in the mechanism of antitumour properties of the metallocenes, as both titanocene dichloride 1 and vanadocene dichloride 2 inhibit DNA and RNA synthesis, and titanium and vanadium accumulate in nucleic acid-rich regions of tumour cells. However, in contrast to the well characterized platinum-based anticancer drugs, the active species responsible for antitumour activity in vivo has not been identified and the mechanism whereby irreparable DNA damage and/or structural modification of DNA or other cellular targets occurs is poorly understood. This review will focus on recent studies that have been carried out in order to identify the biologically active species and more fully understand the molecular level mechanism of action of the metallocene dihalides. Studies with nucleotides, oligonucleotides, DNA and proteins including topoisomerases, protein kinase C and transferrin have provided important insight into potential cellular transport mechanisms and the interaction of metallocenes with biomolecular targets. New structure activity studies including the design of hydrolytically stable metallocenes and the preparation of highly water soluble amino acid analogues have not led to improved anticancer activity of titanocene dichloride 1. The vastly different chemical and hydrolytic stability of each of the metallocenes points to a unique mechanism of action of each metallocene in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Organometallic Anticancer Compounds
Gasser, G., Ott, I., & Metzler-Nolte, N. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm100020w · Cited by 1,624
Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway
Qian, Z. M., Li, H., Sun, H., & Ho, K. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.4.561 · Cited by 1,019
Timerbaev, A. R., Hartinger, C. G., Aleksenko, S. S., & Keppler, B. K. (2006) · Chemical Reviews · doi:10.1021/cr040704h · Cited by 614
Evangelou, A. M. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00221-9 · Cited by 612
Non Platinum Metal Complexes as Anti‐cancer Drugs
Ott, I., & Gust, R. (2007) · Archiv der Pharmazie · doi:10.1002/ardp.200600151 · Cited by 609
Anticancer Activity of Metal Complexes: Involvement of Redox Processes
Jungwirth, U., Kowol, C. R., Keppler, B. K., Hartinger, C. G., Berger, W., & Heffeter, P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3663 · Cited by 554
On the medicinal chemistry of ferrocene
Fouda, M. F. R., Abd‐Elzaher, M. M., Abdelsamaia, R. A., & Labib, A. A. (2007) · Applied Organometallic Chemistry · doi:10.1002/aoc.1202 · Cited by 460
Transferrin/transferrin receptor‐mediated drug delivery
Li, H., & Qian, Z. M. (2002) · Medicinal Research Reviews · doi:10.1002/med.10008 · Cited by 441
Vanadium—an element of atypical biological significance
Mukherjee, B., Patra, B., Mahapatra, S., Banerjee, P., Tiwari, A., & Chatterjee, M. (2004) · Toxicology Letters · doi:10.1016/j.toxlet.2004.01.009 · Cited by 379
Advances in the design of organometallic anticancer complexes
Zhang, P., & Sadler, P. J. (2017) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2017.03.038 · Cited by 369
Hannon, M. J. (2007) · Pure and Applied Chemistry · doi:10.1351/pac200779122243 · Cited by 313
Fahrni, C. J. (2007) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.02.039 · Cited by 297
“com in small spots with very high concentration, thus confirming conclusions from previous chemical speciation studies that suggested a different mechanism of action of the two drugs [43].”
ResultMulticomponent syntheses of functional chromophores
Levi, L., & Müller, T. J. J. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00805k · Cited by 289
The chemistry and biology of vanadium compounds in cancer therapeutics
Kioseoglou, E., Petanidis, S., Gabriel, C., & Salifoglou, A. (2015) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2015.03.010 · Cited by 272
Bioinorganic Chemistry of Titanium
Buettner, K. M., & Valentine, A. M. (2012) · Chemical Reviews · doi:10.1021/cr1002886 · Cited by 262
Metadata
- Authors
- Harding, M., & Mokdsi, G.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2000-12-01
- Volume
- 7
- Issue
- 12
- Pages
- 1289-1303
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W1991588605
- Cited by
- 233
- References
- 0
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.